FILE PHOTO: An Eli Lilly and Firm pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. REUTERS/Mike Segar
Sept 21 (Reuters) – Eli Lilly (LLY.N) on Tuesday introduced a pact with the European Fee to produce as much as 220,000 doses of its COVID-19 twin antibody cocktail to European international locations for sufferers aged 12 years and older who’re at a excessive threat of progressing to extreme illness.
The therapy, a mixture of bamlanivimab and etesevimab, is supposed to be used in sufferers who don’t require supplemental oxygen for COVID-19.
The settlement permits taking part international locations within the European Union and European Financial Space to buy the merchandise immediately from Lilly, following authorization, Lilly stated, including that the portions bought might fluctuate primarily based on native wants.
Whereas numerous European international locations have beforehand ordered bamlanivimab and etesevimab within the first half of the 12 months and have stock readily available, this settlement offers entry to further doses for taking part international locations, ought to they be wanted, Lilly stated.
The drugmaker stated it doesn’t anticipate an impression to its 2021 monetary outlook because of this settlement.
Lilly final week stated the U.S. authorities had purchased 388,000 further doses of its COVID-19 antibody remedy, etesevimab to be paired with the present provide of bamlanivimab. read more
Reporting by Manojna Maddipatla in Bengaluru; Enhancing by Vinay Dwivedi
Our Requirements: The Thomson Reuters Trust Principles.
